CoChat

Clinical outcomes of lung transplant recipients with telomerase mutations

Open access
Tokman, Sofya, Singer, Jonathan P., Devine, Megan S., Westall, Glen P., Aubert, John-David, Tamm, Michael, Snell, Gregory I., Lee, Joyce S., Goldberg, Hilary J., Kukreja, Jasleen, Golden, Jeffrey A., Leard, Lorriana E., Garcia, Christine K., Hays, Steven R. · 2015 · The Journal of Heart and Lung Transplantation
Cited by 109

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background Successful lung transplantation (LT) for patients with pulmonary fibrosis from telomerase mutations is limited by systemic complications of telomerase dysfunction including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes among 14 LT recipients with telomerase mutations. Methods Subjects underwent LT between February 2005 and April 2014 at 5 LT centers. We abstracted data from medical records, focusing on outcomes reflecting post-LT treatment effects likely to be complicated by telomerase mutations. Results The median age of subjects was 60.5 years (IQR 52.0–62.0), 64.3% were male, and the mean post-LT observation time was 3.2 years (SD ±2.9). Eleven subjects had a mutation in telomerase reverse transcriptase, 2 in telomerase RNA component, and 1 had an uncharacterized mutation. Ten subjects were leukopenic post-LT; leukopenia prompted cessation of mycophenolate mofetil in 5 and treatment with filgrastim in 4. Six subjects had recurrent lower respiratory tract infections (LRTI), 7 had acute cellular rejection (ACR) (A1), and 4 developed chronic lung allograft dysfunction (CLAD). Ten LT recipients developed chronic renal insufficiency and 8 experienced acute, reversible renal failure. Three developed cancer, none had cirrhosis. Thirteen subjects were alive at data censorship. Conclusions The clinical course for LT recipients with telomerase mutations is complicated by renal disease, leukopenia prompting a change in the immunosuppressive regimen, and recurrent LTRI. In contrast, cirrhosis was absent, ACR was mild, and development of CLAD was comparable to other LT populations. While posing challenges, lung transplantation may be feasible for patients with pulmonary fibrosis due to telomerase mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2015.05.002

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 109

Metadata

Authors
Tokman, S., Singer, J. P., Devine, M. S., Westall, G. P., Aubert, J.-D., Tamm, M., Snell, G. I., Lee, J. S., Goldberg, H. J., Kukreja, J., Golden, J. A., Leard, L. E., Garcia, C. K., & Hays, S. R.
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2015-10
Volume
34
Issue
10
Pages
1318-1324
ISSN
1053-2498 (ISSN-L)
OpenAlex
W1727581268
Cited by
109
References
8
FWCI
8.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical outcomes of lung transplant recipients with telomerase mutations. https://app.cochat.ai/papers/10.1016/j.healun.2015.05.002
The paper
Tokman, S., Singer, J. P., Devine, M. S., Westall, G. P., Aubert, J.-D., Tamm, M., Snell, G. I., Lee, J. S., Goldberg, H. J., Kukreja, J., Golden, J. A., Leard, L. E., Garcia, C. K., & Hays, S. R. (2015). Clinical outcomes of lung transplant recipients with telomerase mutations. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2015.05.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.